From 2012 to 2016, there was a general trend, starting with the study of tumor development (“tumor progression”) and its diagnosis technology (“positron-emission-tomography”), moving to the molecular (“lipid rafts”, “activated protein-kinase”) and gene level (“ppar-alpha”, “p53”, “ppar-gamma”). The gene discussed is TP53; the disease is neoplasm.